Evidence map›Paper›PMID 38386490›Full record

ArticleMovement disorders clinical practice2024

Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment in Advanced Parkinson's Disease: A Single-Center Study of 30 Patients.

Vili Viljaharju, Tuomas Mertsalmi, K Amande M Pauls, Maija Koivu, Johanna Eerola-Rautio, Marianne Udd, Eero Pekkonen

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders clinical practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Observational
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Observational
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Vili ViljaharjuDepartment of Neurology, Helsinki University Hospital, Helsinki, Finland.
Tuomas MertsalmiDepartment of Neurology, Helsinki University Hospital, Helsinki, Finland.
K Amande M PaulsDepartment of Neurology, Helsinki University Hospital, Helsinki, Finland.
Maija KoivuDepartment of Neurology, Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0002-7921-5412
Johanna Eerola-RautioDepartment of Neurology, Helsinki University Hospital, Helsinki, Finland.
Marianne UddDepartment of Gastroenterological Surgery, Helsinki University Hospital, Helsinki, Finland.
Eero PekkonenDepartment of Neurology, Helsinki University Hospital, Helsinki, Finland.
University of Helsinki · FIHelsinki University Hospital · FI

Funding

Helsingin YliopistoThe Finnish Parkinson Foundation
6 · The paper itself

Abstract

backgroundLevodopa-entacapone-carbidopa intestinal gel (LECIG) is a novel device assisted treatment option for advanced Parkinson's disease (PD). It has been available in Finland since 2020. There is paucity of scientific studies considering LECIG treatment in clinical practice.

objectivesObjectives of this study were to evaluate the changes in medication, adverse events and early discontinuations of LECIG treatment in real life clinical practice.

methodsThe records of 30 consecutive patients, who received LECIG between years 2020 and 2022 in Helsinki University Hospital, were retrospectively analyzed. Data considering changes in medication, discontinuations, and adverse events during the first six months of LECIG treatment was collected.

resultsMean levodopa equivalent daily dose (LEDD) rose significantly between baseline before LECIG and six months with treatment (1230 mg vs. 1570 mg, P = 0.001). Three patients were discarded during nasojejunal tube test phase and seven discontinued the treatment during six-month follow-up. Most common reasons for discontinuation were difficulty in finding suitable infusion rate and neuropsychiatric problems. Safety issues encountered were similar to those reported with levodopa-carbidopa intestinal gel (LCIG) treatment. One case of rhabdomyolysis due to severe dyskinesia during LECIG treatment was observed. Patients were satisfied with the small size of the pump system.

conclusionsLEDD seems to increase during the first months of LECIG treatment. When compared to studies on LCIG, safety profile of LECIG appears similar, but early discontinuation rate is higher than expected. However, long-term studies are lacking. Only clear advantage to LCIG appears to be the smaller LECIG pump size.

Indexed as

CatecholsLevodopaNitrilesParkinson DiseaseAntiparkinson AgentsCarbidopaHumansRetrospective StudiesAntiparkinson AgentsCarbidopaCatecholsentacaponeLevodopaNitrilesadvanced Parkinson's diseaseLECIGlevodopa-entacapone-carbidopa intestinal gel

Identifiers

PMID38386490
PMCPMC10883392
OpenAlexW4388733591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.